DreaMed Advisor Pro

FDA greenlights DreaMed's AI-backed insulin management tool for folks with Type 2 diabetes

By Emily Olsen 11:12 am October 7, 2021

Israel-based DreaMed scored another FDA clearance, expanding the availability of its AI-supported diabetes care platform to Type 2 patients. The Advisor Pro Al Clinical Decision Support System helps healthcare providers manage the insulin needs of patients who use insulin pumps or injections and monitor their glucose levels using a continuous glucose monitor and/or blood glucose meters. The...

FDA grants DreaMed's de novo request for device-friendly diabetes software

By Dave Muoio 08:52 am June 18, 2018

The FDA has granted Isreal-based DreaMed Diabetes a de novo request for its artificial intelligence-powered software for providers managing patients with Type 1 diabetes. “This is an innovation that can improve people’s lives and the FDA decision confirms what we believe is an important step in making a more meaningful connection between the healthcare provider and their type 1 diabetes patients...